Cleared Traditional

K770942 - PHADECODE DIFFERENTIAL FACTOR XA1 ASSAY

K770942 is an FDA 510(k) clearance for PHADECODE DIFFERENTIAL FACTOR XA1 ASSAY, manufactured by Pharmaseal Div., Baxter Healthcare Corp.. The device is a Class 2 Hematology device with product code JBQ cleared through the Traditional 510(k) pathway after a 58-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1977
Decision
58d
Days
Class 2
Risk

K770942 is an FDA 510(k) clearance for the PHADECODE DIFFERENTIAL FACTOR XA1 ASSAY. Classified as Antithrombin Iii Quantitation (product code JBQ), Class II - Special Controls.

Submitted by Pharmaseal Div., Baxter Healthcare Corp. (Mchenry, US). The FDA issued a Cleared decision on July 21, 1977 after a review of 58 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7060 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

FDA 510(k) Submission Details - K770942

510(k) Number K770942 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 24, 1977
Decision Date July 21, 1977
Days to Decision 58 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
55d faster than avg
Panel avg: 113d · This submission: 58d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

JBQ Device Classification - Class 2, Special Controls

Product Code JBQ Antithrombin Iii Quantitation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7060
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - JBQ Antithrombin Iii Quantitation

All 55
Devices cleared under the same product code (JBQ) and FDA review panel - the closest regulatory comparables to K770942.
LAS-R HUMAN ANTITHROMBIN III TEST
K772328 · Hyland Therapeutic Div., Travenol Laboratories · Feb 1978
ANTITHROMBIN III ASSAY
K780002 · Ortho Diagnostics, Inc. · Jan 1978
DIAG. KIT FOR TOTAL ANTITHROMBIN III
K771669 · Abbott Laboratories · Nov 1977
THROMBO-SCREEN AT-111 KIT
K770394 · Bay Area Hema. Onco. Clinic. & Res. L · Mar 1977